發炎性腸道疾病市場按藥物類別、適應症、給藥途徑、分銷管道和地區分類

2025 年全球發炎性腸道疾病市場規模估計為 233.4 億美元，預計到 2032 年將達到 320 億美元，2025 年至 2032 年的複合年成長率為 4.6%。

數字。 2025 年發炎性腸道疾病市場佔有率（按地區分類）

發炎性腸道疾病腸道疾病(IBD) 是指兩種疾病－克隆氏症和潰瘍性大腸炎－其特徵是消化道慢性發炎。 IBD 主要影響小腸和大腸，但有時會擴散到消化器官系統的其他部位。 IBD 的典型症狀因患者而異，但通常包括反覆腹痛、腹瀉、嘔吐、體重減輕和疲勞。儘管確切的原因尚不清楚，但人們認為 IBD 是在遺傳易感個體對環境觸發因素的免疫反應調節不當而發生的。目前可用的治療方法旨在透過針對免疫系統的不同組成部分來誘導和維持緩解。由於這些治療方法無法治癒IBD，因此IBD在世界範圍內仍然是一個沉重的臨床和經濟負擔。

市場動態

全球發炎性腸道疾病市場的發展主要受到生活方式改變、環境風險增加和已開發國家預期壽命增加導致克隆氏症和潰瘍性大腸炎盛行率上升的推動。此外，致力於開發新型選擇性和個人化療法的研究和開發不斷增加、對 IBD 早期診斷和管理的認知不斷提高以及主要市場的醫療保健支出不斷增加也在推動市場成長。然而，嚴格的藥物開發法規以及與 IBD 診斷工具和藥物相關的高成本可能會阻礙市場的成長。生技藥品、幹細胞、基因治療等領域的先進研究和開發可能為相關人員提供豐厚的機會。

研究的主要特點

• 本報告對全球發炎性腸道疾病市場進行了詳細分析，並提供了預測期（2025-2032 年）的市場規模（十億美元）和年複合成長率（CAGR%），假設基準年為 2024 年。
• 它還強調了各個領域的潛在商機並說明了該市場的有吸引力的投資提案矩陣。
• 它還提供了對市場促進因素、限制因素、機會、新產品發布和核准、市場趨勢、區域前景以及主要企業採用的競爭策略的重要見解。
• 本報告的見解將使負責人和企業經營團隊能夠就未來產品發布、高階市場策略、市場擴張和行銷策略做出明智的決策。
• 全球發炎性腸道疾病市場報告迎合了該行業的各個相關人員，例如投資者、供應商、產品製造商、經銷商、新進入者和金融分析師。
• 相關人員將透過全球發炎性腸道疾病市場分析中使用的各種策略矩陣更輕鬆地做出決策。

目錄

第1章 調查目的與前提條件

• 研究目標
• 先決條件
• 簡稱

第2章 市場展望

• 報告描述
  • 市場定義和範圍
• 執行摘要
• 一致的機會圖 (COM)

第3章市場動態、法規與趨勢分析

• 市場動態
  • 驅動程式
  • 限制因素
  • 機會
• 影響分析
• 市場趨勢
• 監管情景
• 收購和合作場景
• 資金籌措和投資
• PEST分析
• 波特的分析

4. 全球發炎性腸道疾病市場 - 冠狀病毒 (COVID-19) 大流行的影響

• 整體影響
• 政府舉措
• COVID-19 市場影響

5. 2020 年至 2032 年全球發炎性腸道疾病市場（按藥物類別分類）（十億美元）

• 介紹
• 皮質類固醇
• 胺基水楊酸
• TNF 抑制劑
• 免疫抑制劑
• 抗生素
• 其他

6. 2020 年至 2032 年全球發炎性腸道疾病市場（依適應症分類）（十億美元）

• 介紹
• 潰瘍性大腸炎
• 克隆氏症

7. 2020 年至 2032 年全球發炎性腸道疾病市場，依給藥途徑分類（十億美元）

• 介紹
• 口服
• 注射

8. 2020-2032 年全球發炎性腸道疾病市場按分銷管道分類（十億美元）

• 介紹
• 醫院藥房
• 零售藥局
• 網路藥局

9. 2020 年至 2032 年全球發炎性腸道疾病市場（按地區分類）（十億美元）

• 介紹
• 北美洲
• 拉丁美洲
• 歐洲
• 亞太地區
• 中東
• 非洲

第10章 競爭格局

• 公司簡介
  • AbbVie Inc.
  • Johnson & Johnson Services, Inc.
  • Takeda Pharmaceutical Company Limited
  • Biogen
  • Amgen Inc.
  • UCB SA
  • Novartis AG
  • Merck &Co., Inc.
  • Pfizer Inc.
  • Eli Lilly and Company
  • Gilead Sciences
  • Bausch Health Companies Inc.
  • Celltrion Healthcare Co., Ltd.
  • CELGENE CORPORATION
  • COSMO PHARMACEUTICALS
  • Innovate Biopharmaceuticals
  • Sandoz
  • Horizon Therapeutics

第 11 章 分析師建議

• 興衰
• 一致的機會地圖

第 12 章參考文獻與調查方法

• 參考
• 調查方法

Global Inflammatory Bowel Disease Market is estimated to be valued at USD 23.34 Bn in 2025 and is expected to reach USD 32.00 Bn by 2032, growing at a compound annual growth rate (CAGR) of 4.6% from 2025 to 2032.

Figure. Inflammatory Bowel Disease Market Share (%), By Region 2025

Inflammatory bowel disease (IBD) refers to two conditions - Crohn's disease and ulcerative colitis - that are characterized by chronic inflammation within the gastrointestinal tract. IBD predominantly affects the small and large intestines but can sometimes extend throughout other areas of the digestive system. Typical symptoms of IBD vary between patients but often include recurring abdominal pain, diarrhea, vomiting, weight loss, and fatigue. While the precise etiologies remain unclear, IBD is believed to arise due to inappropriately regulated immune responses to environmental triggers in genetically susceptible individuals. Currently available treatment options aim to induce and maintain remission by targeting different components of the immune system. As these approaches are not curative, IBD poses a substantial clinical and economic burden worldwide.

Market Dynamics:

Global inflammatory bowel disease market growth is primarily driven by rising prevalence of Crohn's disease and ulcerative colitis due to lifestyle changes, growing environmental risks, and prolonged lifespan in developed nations. Increasing research activities focused on developing novel selective and personalized therapies, growing awareness about early diagnosis and management of IBD, and rising healthcare expenditure across major markets can also drive the market growth. However, stringent drug development regulations and high costs associated with IBD diagnostic tools and medications can hamper the market growth. Ongoing R&D in biologics, stem cell and gene-based therapies can offer lucrative opportunities for stakeholders.

Key Features of the Study:

• This report provides in-depth analysis of the global inflammatory bowel disease market, and provides market size (USD Billion) and compound annual growth rate (CAGR%) for the forecast period (2025-2032), considering 2024 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
• Key companies covered as a part of this study include AbbVie, Janssen Biotech, Takeda Pharmaceutical, UCB, and Pfizer
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• Global inflammatory bowel disease market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global inflammatory bowel disease market

Detailed Segmentation-

• By Drug Class
  • Corticosteroids
  • Aminosalicylates
  • TNF Inhibitors
  • Immunosuppressant
  • Antibiotics
  • Others
• By Disease Indication
  • Ulcerative Colitis
  • Crohn's Disease
• By Route of Administration
  • Oral
  • Injectable
• By Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
• By Region
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East
  • Africa
• Company Profiles:
  • AbbVie Inc.
  • Johnson & Johnson Services, Inc.
  • Takeda Pharmaceutical Company Limited
  • Biogen
  • Amgen Inc.
  • UCB S.A.
  • Novartis AG
  • Merck & Co., Inc.
  • Pfizer Inc.
  • Eli Lilly and Company
  • Gilead Sciences
  • Bausch Health Companies Inc.
  • Celltrion Healthcare Co., Ltd.
  • CELGENE CORPORATION
  • COSMO PHARMACEUTICALS
  • Innovate Biopharmaceuticals
  • Sandoz
  • Horizon Therapeutics

Table of Contents

1. Research Objectives and Assumptions

• Research Objectives
• Assumptions
• Abbreviations

2. Market Purview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Market Snapshot, By Drug Class
  • Market Snapshot, By Disease Indication
  • Market Snapshot, By Route of Administration
  • Market Snapshot, By Distribution Channel
  • Market Snapshot, By Region
• Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
  • Drivers
  • Restraints
  • Opportunities
• Impact Analysis
• Market Trends
• Key Developments
• Regulatory Scenario
• Acquisitions and Partnerships Scenario
• Funding and Investments
• PEST Analysis
• Porter's Analysis

4. Global Inflammatory Bowel Disease Market- Impact of Coronavirus (COVID-19) Pandemic

• Overall Impact
• Government Initiatives
• COVID-19 Impact on the Market

5. Global Inflammatory Bowel Disease Market, By Drug Class, 2020 - 2032, (USD Bn)

• Overview
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2020 - 2032
  • Segment Trends
• Corticosteroids
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Aminosalicylates
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• TNF Inhibitors
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Immunosuppressant
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Antibiotics
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Others
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

6. Global Inflammatory Bowel Disease Market, By Disease Indication, 2020 - 2032, (USD Bn)

• Overview
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2020 - 2032
  • Segment Trends
• Ulcerative Colitis
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Crohn's Disease
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

7. Global Inflammatory Bowel Disease Market, By Route of Administration, 2020 - 2032, (USD Bn)

• Overview
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2020 - 2032
  • Segment Trends
• Oral
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Injectable
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

8. Global Inflammatory Bowel Disease Market, By Distribution Channel, 2020 - 2032, (USD Bn)

• Overview
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2020 - 2032
  • Segment Trends
• Hospital Pharmacies
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Retail Pharmacies
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Online Pharmacies
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

9. Global Inflammatory Bowel Disease Market, By Region, 2020 - 2032, (USD Bn)

• Introduction
  • Market Share Analysis, By Region, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, For Region, 2020-2032
  • Regional Trends
• North America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Disease Indication, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Bn)
    • U.S.
    • Canada
• Latin America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Disease Indication, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Bn)
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
• Europe
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Disease Indication, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Bn)
    • U.K.
    • Germany
    • Italy
    • France
    • Spain
    • Russia
    • Rest of Europe
• Asia Pacific
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Disease Indication, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Bn)
    • China
    • India
    • Japan
    • ASEAN
    • Australia
    • South Korea
    • Rest of Asia Pacific
• Middle East
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Disease Indication, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Bn)
    • GCC Countries
    • Israel
    • Rest of Middle East
• Africa
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Disease Indication, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2020 - 2032, (USD Bn)
    • North Africa
    • Central Africa
    • South Africa

10. Competitive Landscape

• Company Profiles
  • AbbVie Inc.
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Johnson & Johnson Services, Inc.
  • Takeda Pharmaceutical Company Limited
  • Biogen
  • Amgen Inc.
  • UCB S.A.
  • Novartis AG
  • Merck & Co., Inc.
  • Pfizer Inc.
  • Eli Lilly and Company
  • Gilead Sciences
  • Bausch Health Companies Inc.
  • Celltrion Healthcare Co., Ltd.
  • CELGENE CORPORATION
  • COSMO PHARMACEUTICALS
  • Innovate Biopharmaceuticals
  • Sandoz
  • Horizon Therapeutics

11. Analyst Recommendations

• Wheel of Fortune
• Analyst View
• Coherent Opportunity Map

12. References and Research Methodology

• References
• Research Methodology
• About us and Sales Contact